



## Rexulti<sup>®</sup> (brexpiprazole) – New warning

- On February 9, 2018, the FDA approved an update to the *Warning and Precautions* section of the [Rexulti \(brexpiprazole\)](#) drug label regarding pathological gambling and other compulsive behaviors.
- Rexulti is approved for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and treatment of schizophrenia.
- Post-marketing case reports suggest that patients can experience intense urges, particularly for gambling, and the inability to control these urges while taking Rexulti. Other compulsive urges, reported less frequently, include: sexual urges, shopping, eating or binge eating, and other impulsive or compulsive behaviors.
  - Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or intense gambling urges, compulsive sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with Rexulti.
  - In some cases, although not all, urges were reported to have stopped when the dose was reduced or the medication was discontinued.
  - Compulsive behaviors may result in harm to the patient and others if not recognized. Consider dose reduction or stopping the medication if a patient develops such urges.
- Rexulti carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis; and suicidal thoughts and behaviors.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.